Proper functioning of the central nervous system (CNS) is critically dependent on the formation of insulating myelin sheaths around axons. Myelination is a complex multi-step process that occurs primarily during early postnatal life, but it is also re-initiated in the adult CNS in response to acute demyelination insults. Dysfunction o myelin-forming cells and/or loss of myelin sheath underlie many neurological disorders including multiple sclerosis (MS) and psychological disorders such as schizophrenia. Promoting myelin repair and achieving neuroprotection has attracted increasing attention, and several pharmaceutical companies and research laboratories including ours are actively pursuing the discovery of drug-like small molecules that promote such processes. However, one of the major roadblocks in this effort is the lack of robust in vitro CNS myelination models. Our multidisciplinary research team has recently developed a microfluidic CNS neural stem/progenitor cell (NSPC) aggregate culture system that for the first time demonstrated robust myelin ensheathment of cortical neurons in vitro using a microdevice. The major advantages of this aggregate culture system are that it contains all the essential cellular components of an in vivo environment. However the use of this microdevice is labor intensive and throughput is quite limited. Here we propose to develop a high-throughput microfluidic NSPC aggregate culture system that provides at least two orders of magnitude higher throughput than existing approaches including ours, establishing for the first time a high-throughput in vitro CNS myelination model that has physiologically relevant neuronal responses and is amenable to drug screening applications. The innovative three-dimensional high-throughput screening (3D-HTS) microsystem will have at least three sets of 100 independently controlled microscale culture compartments (300 total), each compartment having eight aggregate trapping sites. The fully automated system will enable screening the effects of 20 candidate drug molecules at 5 different concentrations each, with 3 repeats per condition, all in a single experimental run. The microfluidic system configuration is flexible, where it can be easily re-configured to screen large number of candidate drug molecules with fewer number of concentrations tested. As image processing is another major bottleneck for high-throughput screening, we will develop an image processing algorithm that will minimize the number of images required for myelin segment quantification and fully automate the image processing steps for the large number of immunostained images that will be generated. We will conduct a proof-of-concept drug screening assay using this microfluidic system. This will be the first in vitro myelinating system recapitulating cortical axon-glial interactions and one that is fully adaptable to automation of th entire drug screening assay. We expect that the successful development of this high-throughput platform will lead to a routine drug screening system for identifying potential targets or candidate drug molecules that can stimulate myelin repair and help recover function in demyelinating diseases and other neurological disorders.

Public Health Relevance

We propose to develop a high-throughput microfluidic NSPC aggregate culture system that provides at least two orders of magnitude higher throughput, establishing for the first time a high-throughput in vitro CNS myelination model that has physiologically relevant neurological responses and is amenable for drug screening applications. It is our hope that upon completion, this proposal will lead to a new method/tool that can be utilized to unravel the mechanisms of CNS myelinogenesis and lead to the discovery of novel small molecules that can stimulate remyelination, laying a solid foundation for the next phase of translational investigation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21EB021005-02
Application #
9144786
Study Section
Bioengineering of Neuroscience, Vision and Low Vision Technologies Study Section (BNVT)
Program Officer
Selimovic, Seila
Project Start
2015-09-15
Project End
2017-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Texas Engineering Experiment Station
Department
Engineering (All Types)
Type
Biomed Engr/Col Engr/Engr Sta
DUNS #
847205572
City
College Station
State
TX
Country
United States
Zip Code
77845
Jeong, Sehoon; Kim, Sunja; Buonocore, John et al. (2018) A Three-Dimensional Arrayed Microfluidic Blood-Brain Barrier Model With Integrated Electrical Sensor Array. IEEE Trans Biomed Eng 65:431-439
Kim, Hyun Soo; Jeong, Sehoon; Koo, Chiwan et al. (2016) A Microchip for High-throughput Axon Growth Drug Screening. Micromachines (Basel) 7:
Park, Jaewon; Kim, Sunja; Park, Su Inn et al. (2014) A microchip for quantitative analysis of CNS axon growth under localized biomolecular treatments. J Neurosci Methods 221:166-74